Skip to main content
Ind-Swift Laboratories Ltd. logo

Ind-Swift Laboratories Ltd. — Investor Relations & Filings

Ticker · INDSWFTLAB ISIN · INE915B01019 LEI · 335800ZT8UFD9Y8ZMP56 BSE.NS Manufacturing
Open in API
Filings indexed 816 across all filing types
Latest filing 2024-03-28 Major Shareholding Noti…
Country IN India
Listing BSE.NS INDSWFTLAB

About Ind-Swift Laboratories Ltd.

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd. is a global manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. The company focuses on research and development, process chemistry, and large-scale production across diverse therapeutic segments, including macrolide antibiotics, cardiovascular agents, antihistamines, antidiabetics, and antipsychotics. Operating multiple manufacturing facilities that adhere to international regulatory standards such as USFDA, EDQM, and PMDA, the organization provides high-quality chemical entities to the global market. Its core competencies lie in complex chemical synthesis and the development of cost-effective manufacturing processes for generic and specialty drug substances. The company maintains a strong emphasis on quality assurance and regulatory compliance to support its extensive portfolio of products distributed worldwide.

Recent filings

Filing Released Lang Actions
Updates
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. It details the sale of shares by Edelweiss Alternative Asset Advisors Limited and related funds, including the number of shares sold, percentage of equity capital, and changes in shareholding before and after the sale. The document is a formal notification to stock exchanges about a substantial acquisition or disposal of shares, which fits the definition of a Major Shareholding Notification (MRQ). It is not an annual report, earnings release, or any other financial report, nor is it a proxy, governance, or legal filing. The content is specific to changes in significant share ownership levels crossing thresholds, which aligns with the MRQ category.
2024-03-28 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding an amendment to the terms of a Business Transfer Agreement (BTA) and Shareholders' Agreement with Synthimed Labs Private Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content details changes in investment terms and shareholding percentages, indicating an update on a financing or capital structure matter. There is no financial statement or comprehensive financial analysis present, nor is this a report or presentation. The document is a regulatory announcement about a capital/financing update related to convertible debentures and equity holding changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-03-21 English
Change in Management
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding changes in key managerial personnel (KMP) of the company. It specifically informs about the cessation of the CEO and Chief Accounts Officer due to a business transfer agreement. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in directors or key management personnel. The content includes detailed annexures about the individuals and the reasons for their cessation. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of changes in the company's board or senior management, fitting the category of Board/Management Information (MANG).
2024-03-18 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the completion of early redemption of Non-Convertible Debentures (NCDs). It references compliance with Regulation 15(9) of SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021. The content is a notification of a completed financial transaction (early redemption of debt securities) with details such as issue size, coupon rate, redemption amount, and dates. The document length is 3600 characters, which is relatively short and primarily serves as an announcement rather than a detailed financial report or audit. It does not contain financial statements or detailed analysis but reports a capital structure event. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on a financing activity (redemption of debentures).
2024-03-18 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the full redemption of principal and interest payments on a specific non-convertible debenture issue. It references Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to timely payment of interest and principal on listed debt securities. The document details the payment amounts, dates, and confirms that the debentures have been fully redeemed. There is no financial statement or comprehensive financial analysis present, nor is it a report or presentation. It is an update on a capital/financing event related to debt redemption. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 4074 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2024-03-18 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the completion of a slump sale transaction of a business segment (Active Pharmaceutical Ingredients and CRAMS) by the company Ind-Swift Laboratories Limited. It references prior communications about the approval and expected closing dates of the transaction and informs about the actual closing date. The document is an update on a capital transaction rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather a regulatory disclosure about a financing-related event. The reference to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events, supports classification as a Capital/Financing Update. The document length is short (2846 characters), and it is not announcing a report publication but an event completion. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-03-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.